 |
|
MVA-PSA-PAP prostate cancer vaccine| A cancer vaccine consisting of a recombinant modified vaccinia Ankara (MVA) viral vector encoding genes for prostate specific antigen (PSA) and prostate acid phosphatase (PAP) with potential immunostimulatory and antineoplastic activities. Upon administration, MVA-PSA-PAP prostate cancer vaccine
expresses PSA and PAP peptides, which may elicit humoral and cellular immune responses against prostate cancer cells expressing PSA and PAP. Multi-antigen vaccine therapy may be more efficacious than single-antigen therapy vaccine therapy.
Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) |
| Mycelex Troche| (Other name for: clotrimazole) |
| Mycobacterium w| An attenuated strain of Mycobacterium w, a non-pathogenic, rapidly growing, atypical mycobacterium, with non-specific immunopotentiating properties. In addition to sharing a number of common B and T cell determinants with Mycobacterium leprae and Mycobacterium tuberculosis, Mycobacterium w (Mw) also shares an immunogenic determinant with prostate specific antigen (PSA). In vitro and in vivo studies have shown that heat-killed Mw can induce significant T-cell responses. This agent may induce host T-cell responses against tumor cells expressing PSA. PSA is a glycoprotein secreted by prostatic epithelial and ductal cells and may be overexpressed in prostate cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) |
| Mycobutin| (Other name for: rifabutin) |
| mycophenolate mofetil| The morpholinoethyl ester of mycophenolic acid (MPA) with potent immunosuppressive properties. Mycophenolate stops T-cell and B-cell proliferation through selective inhibition of the de novo pathway of purine biosynthesis. In vivo, the active metabolite, MPA, reversibly inhibits inosine 5'-monophosphate dehydrogenase, an enzyme involved in the de novo synthesis of guanine nucleotides. MPA displays high lymphocyte specificity and cytotoxicity due to the higher dependence of activated lymphocytes on both salvage and de novo synthesis of guanine nucleotides relative to other cell types. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) |
| Myleran| (Other name for: busulfan) |
| Mylosar| (Other name for: azacitidine) |
| Mylotarg| (Other name for: gemtuzumab ozogamicin) |
| Mylovenge| (Other name for: idiotype-pulsed autologous dendritic cell vaccine APC8020) |
| Myochrysine| (Other name for: gold sodium thiomalate) |
|
Back to Top
< Previous 1 2
|
|
